Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer
NCT ID: NCT06581679
Last Updated: 2024-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
184 participants
INTERVENTIONAL
2023-12-15
2024-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
While there are treatments available for adenomyosis, they are often limited due to the lack of precise diagnostic criteria. One common approach is the use of gonadotropin-releasing hormone agonist (GnRHa), which can improve pregnancy rates in infertile women with adenomyosis. However, it's important to note that GnRHa may not restore pregnancy rates to baseline levels.
Another potential treatment option is the levonorgestrel-releasing intrauterine system (LNG-IUS). This device releases a hormone called levonorgestrel into the uterus, which can help control the symptoms of endometriosis and adenomyosis. Studies have shown that the endometrial concentration of levonorgestrel from the LNG-IUS is significantly higher than in other tissues like the myometrium, fallopian tubes, and fat tissue.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ambispective Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin
NCT05152667
Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility
NCT02399501
Endometrial Injury for Unexplained Infertility
NCT02863198
Does Myomectomy for Intramural Fibroid Improve ART Outcome?
NCT03796130
Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome
NCT04741295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The levonorgestrel-releasing intrauterine system Group
levonorgestrel-releasing intrauterine system
The levonorgestrel-releasing intrauterine system releasing 20 levonorgestrel daily.
frozen embryo transfer
Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.
The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur.
GnRHa Group
Triptorelin
GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
frozen embryo transfer
Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.
The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triptorelin
GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
levonorgestrel-releasing intrauterine system
The levonorgestrel-releasing intrauterine system releasing 20 levonorgestrel daily.
frozen embryo transfer
Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.
The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
30 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Walid Mohamed Elnagar
Assistant professor of Obstetrics & Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zagazig university
Zagazig, Ash Sharqia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZU-IRB#506 11/8-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.